Clinical Trials Logo

Diabetic Neuropathies clinical trials

View clinical trials related to Diabetic Neuropathies.

Filter by:

NCT ID: NCT00044421 Completed - Diabetes Mellitus Clinical Trials

Treatment of Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044408 Completed - Clinical trials for Diabetic Neuropathies

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044395 Completed - Clinical trials for Diabetic Neuropathies

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00043797 Active, not recruiting - Clinical trials for Diabetic Polyneuropathy

Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

Start date: n/a
Phase: Phase 2
Study type: Interventional

This clinical trial is to determine an effective dosage and to study the safety of an investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression of diabetic peripheral neuropathy.

NCT ID: NCT00034788 Terminated - Diabetic Foot Clinical Trials

A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

Start date: December 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of REGRANEX® Gel compared with placebo when applied for up to 52 consecutive weeks to recurring or non-healing ulcers of the ankle or foot related to diabetes.

NCT ID: NCT00004647 Completed - Pain Clinical Trials

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

Start date: March 1993
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.

NCT ID: NCT00004407 Terminated - Clinical trials for Diabetic Neuropathies

Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy

Start date: February 1998
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the effect of intravenous immunoglobulin on recovery time of patients with proximal diabetic neuropathy. II. Determine whether rate of response is dose dependent in these patients.

NCT ID: NCT00001344 Completed - Herpes Zoster Clinical Trials

Dextromethorphan Versus Placebo for Neuropathic Pain

Start date: March 1993
Phase: Phase 2
Study type: Interventional

In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by sensitization of central nervous system neurons caused by excitatory amino acid neurotransmitters, acting largely through NMDA receptors. A previous small trial of dextromethorphan suggested efficacy in diabetic neuropathy pain. The study requires one visit to the NIH outpatient Pain Research Clinic, and consists of three 9-week treatment periods. Patients who respond to one of the medications will be invited to participate in further controlled studies of the medication followed by up to several years of open-label treatment under continued observation.